Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.61 |
| ▸ | TGM2 | P21980 | 1/20 | 0.57 |
| ▸ | KRAS | P01116 | 10/20 | 0.56 |
| ▸ | HINT1 | P49773 | 1/20 | 0.55 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.54 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.52 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.52 |
| ▸ | IMPDH2 | P12268 | 4/20 | 0.52 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25569409 | 0.90 | NT5E (0.58) | NT5ETGM2KRASHINT1FUT5 | |
| SCHEMBL25569380 | 0.85 | P2RY1 (0.63) | NT5ETAS1R3TAS1R1 | |
| SCHEMBL25070727 | 0.84 | TGM2 (0.63) | NT5ETGM2KRASHINT1FUT5 | |
| SCHEMBL25070718 | 0.83 | TGM2 (0.65) | NT5ETGM2KRASHINT1FUT5 | |
| SCHEMBL10037916 | 0.82 | NT5E (0.68) | NT5ETGM2KRASHINT1FUT5 | |
| SCHEMBL10067882 | 0.82 | NT5E (0.68) | NT5ETGM2KRASHINT1FUT5 | |
| SCHEMBL13638722 | 0.82 | NT5E (0.68) | NT5ETGM2KRASHINT1FUT5 | |
| SCHEMBL5828417 | 0.82 | NT5E (0.68) | NT5ETGM2KRASHINT1FUT5 | |
| SCHEMBL9976681 | 0.82 | NT5E (0.68) | NT5ETGM2KRASHINT1FUT5 | |
| SCHEMBL2315499 | 0.81 | NT5E (0.69) | NT5ETGM2KRASHINT1FUT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312635-A1 | METHOD FOR PRODUCING NUCLEIC ACID OLIGOMER | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2023-10-05 | — | — | US | disclosed |
| US-20230242570-A1 | METHOD FOR PRODUCING NUCLEIC ACID OLIGOMER | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2023-08-03 | — | — | US | disclosed |
| US-20230167152-A1 | METHOD FOR PRODUCING NUCLEIC ACID OLIGOMER | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312635-A1 | METHOD FOR PRODUCING NUCLEIC ACID OLIGOMER | POLRMT, RNGTT, POLM | NT5E 106/4885TGM2 4199/4885KRAS 1405/4885 |
| US-20230167152-A1 | METHOD FOR PRODUCING NUCLEIC ACID OLIGOMER | POLI, POLL, DNMT3A | NT5E 287/4885TGM2 2804/4885KRAS 526/4885 |
| US-20230242570-A1 | METHOD FOR PRODUCING NUCLEIC ACID OLIGOMER | FBL, POLI, POLL | NT5E 196/4885TGM2 2103/4885KRAS 2021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.